Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.

Cheng, Cho-Chin; Platen, Louise; Christa, Catharina; Tellenbach, Myriam; Kappler, Verena; Bester, Romina; Liao, Bo-Hung; Holzmann-Littig, Christopher; Werz, Maia; Schönhals, Emely; Platen, Eva; Eggerer, Peter; Tréguer, Laëtitia; Küchle, Claudius; Schmaderer, Christoph; Heemann, Uwe; Renders, Lutz; Protzer, Ulrike; Braunisch, Matthias Christoph

doi:10.3390/vaccines10081328

Benutzer: Gast

journal article

Titel:: Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.
Dokumenttyp:: Journal Article
Autor(en):: Cheng, Cho-Chin; Platen, Louise; Christa, Catharina; Tellenbach, Myriam; Kappler, Verena; Bester, Romina; Liao, Bo-Hung; Holzmann-Littig, Christopher; Werz, Maia; Schönhals, Emely; Platen, Eva; Eggerer, Peter; Tréguer, Laëtitia; Küchle, Claudius; Schmaderer, Christoph; Heemann, Uwe; Renders, Lutz; Protzer, Ulrike; Braunisch, Matthias Christoph
Abstract:: Hemodialysis patients are exposed to a markedly increased risk when infected with SARS-CoV-2. To date, it is unclear if hemodialysis patients benefit from four vaccinations. A total of 142 hemodialysis patients received four COVID-19 vaccinations until March 2022. RDB binding antibody titers were determined in a competitive surrogate neutralization assay. Vero-E6 cells were infected with SARS-CoV-2 variants of concern (VoC), Delta (B.1.617.2), or Omicron (B.1.1.529, sub-lineage BA.1) to determine serum infection neutralization capacity. Four weeks after the fourth vaccination, serum infection neutralization capacity significantly increased from a 50% inhibitory concentration (IC50, serum dilution factor 1:x) of 247.0 (46.3-1560.8) to 2560.0 (1174.0-2560.0) for the Delta VoC, and from 37.5 (20.0-198.8) to 668.5 (182.2-2560.0) for the Omicron VoC (each p < 0.001) compared to four months after the third vaccination. A significant increase in the neutralization capacity was even observed for patients with high antibody titers after three vaccinations (p < 0.001). Ten patients with SARS-CoV-2 breakthrough infection after the first blood sampling had by trend lower prior neutralization capacity for Omicron (p = 0.051). Our findings suggest that hemodialysis patients benefit from a fourth vaccination in particular in the light of the highly infectious SARS-CoV-2 Omicron-variants. A routinely applied four-time vaccination seems to broaden immunity against variants and would be recommended in hemodialysis patients.
Zeitschriftentitel:: Vaccines (Basel)
Jahr:: 2022
Band / Volume:: 10
Heft / Issue:: 8
Volltext / DOI:: doi:10.3390/vaccines10081328
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/36016216
TUM Einrichtung:: Institut für Virologie (Prof. Protzer); Professur für Nephrologie (Prof. Heemann)
BibTeX